한글목차

2024년에는 GlobalData의 간성뇌증에 관한 역학 예측에서 다루어지고 있는 16개국에서 450만 명 이상의 진단된 간성뇌증 유병 사례가 예측됩니다. 현재 HE 치료제로서 승인되고 있는 신약은 1품목입니다.

HE의 연구개발 활동은 완만하고, 파이프라인에는 12 분자가 존재하며, 이 중 제III상은 단 1제, 제II상은 6제입니다.

미국은 HE 임상시험을 시행하는 주요 국가로서 부상하고 있습니다. 과거 10년간 북미에서는 파트너십과 라이선싱 계약이 주류였습니다.

세계의 간성뇌증 시장에 대해 조사했으며, 질환의 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등을 제공하고 있습니다.

목차

제1장 목차

제1장 서문

제2장 주요 조사 결과

제3장 병의 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 출시 약제
• 작용기서별 개요
• 분자 유형별 개요
• 제품 개요와 판매 예측

제5장 가격결정과 상환 평가

• 연간 치료비
• 가격결정과 상환까지의 시간

제6장 파이프라인 약제 평가

• 중기부터 후기 단계 파이프라인 약제
• 개발 단계별 개요
• 작용기서별 개요
• 분자 유형별 개요
• 약제 고유 상전이 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증별 PTSR와 LoA

제7장 임상시험 평가

• 역사적 개요
• 상별 개요
• 현황별 개요
• 진행중 및 계획중 시험 상별 개요
• 가상 컴포넌트를 사용한 임상시험
• 지역적 개요
• 지역별 단일국 및 다국적 시험
• 상위 20 스폰서와 상별 내역
• 상위 20 스폰서의 현황별 내역
• 엔드포인트 현황별 개요
• 인종 및 민족별 개요
• 등록 데이터
• 임상시험 사이트 상위 20국
• 세계의 TOP 20 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래의 상황

제9장 상업적 평가

• 주요 시장 참여 기업

제10장 향후 시장 성장 촉진요인

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Hepatic Encephalopathy therapeutics.

• In 2024, more than 4.5 million diagnosed prevalent cases of HE are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for HE.
• Currently, there is a single approved innovator drug available in the market for HE.
• R&D activities for HE are moderate with 12 molecules in the pipeline, out of which Phase III holds only one drug, whereas Phase II holds six drugs.
• The US is emerging as the key country for conducting HE trials.
• During the past decade, partnerships and licensing agreements were the predominant deal types in North America.

Scope

GlobalData's Hepatic Encephalopathy: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Hepatic Encephalopathy market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hepatic Encephalopathy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer